Exposure–Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit–Risk Assessment in Rheumatoid Arthritis

Exposure–response analyses of upadacitinib (UPA) key efficacy and safety end points (3,685 and 4,577 subjects for efficacy and safety, respectively) using data from phase II and phase III rheumatoid arthritis (RA) studies were conducted to support benefit–risk assessment. Percentage of subjects achi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nader, Ahmed, Mohamed, Mohamed‐Eslam F., Winzenborg, Insa, Doelger, Eva, Noertersheuser, Peter, Pangan, Aileen L., Othman, Ahmed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158206/
https://www.ncbi.nlm.nih.gov/pubmed/31610021
http://dx.doi.org/10.1002/cpt.1671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158206/
https://www.ncbi.nlm.nih.gov/pubmed/31610021
http://dx.doi.org/10.1002/cpt.1671

Ejemplares similares